Epinastine is used for the prevention of ocular itching associated with allergic conjunctivitis. Safety and efficacy of epinastine for this use have been evaluated in conjunctival antigen challenge studies and in environmental field studies in over 300 patients 9 years of age and older with allergic conjunctivitis. Results of these studies indicate that epinastine hydrochloride 0.05% solution was more effective than vehicle in providing relief of ocular itching associated with allergic conjunctivitis.
Avoidance of allergen and other triggering factors (e.g., irritants) and application of cold compresses and lubricating eye drops are the initial means of managing allergic conjunctivitis. Drug therapy generally is reserved for use when such avoidance is not possible or is ineffective and can include both prophylactic (e.g., mast-cell stabilizers) and symptomatic (e.g., topical and/or systemic antihistamines, topical vasoconstrictors, topical steroid and nonsteroidal anti-inflammatory agents [NSAIAs]) therapy. The specific therapy(ies) employed will depend on the characteristics and severity of the allergic conjunctivitis. For patients with seasonal allergic conjunctivitis, prophylaxis with a mast-cell stabilizer often is initiated before and maintained throughout the pollen season, and symptomatic therapy with other agents (e.g., topical antihistamines, topical NSAIAs) generally is initiated as necessary to provide acute relief. Topical corticosteroids usually are reserved for short-term use in patients with moderate to severe symptoms of allergic conjunctivitis.